Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 2/20 | 0.55 |
| ▸ | BCR | P11274 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GPR183 | P32249 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506219 | 0.83 | HPGD (0.71) | HPGDALDH1A1HSD17B10L3MBTL3LMNA | |
| SCHEMBL971083 | 0.82 | HPGD (1.00) | HPGDALDH1A1CA12CA1CA2 | |
| SCHEMBL644199 | 0.82 | HPGD (0.92) | HPGDALDH1A1CA12CA1CA2 | |
| SCHEMBL3152770 | 0.81 | HPGD (0.69) | HPGDALDH1A1HSD17B10CA12CA1 | |
| SCHEMBL18920327 | 0.81 | HPGD (0.69) | HPGDALDH1A1HSD17B10L3MBTL3KMT2A | |
| SCHEMBL20460601 | 0.81 | HPGD (0.69) | HPGDALDH1A1HSD17B10L3MBTL3MGLL | |
| SCHEMBL20460602 | 0.81 | HPGD (1.00) | HPGDALDH1A1HSD17B10KMT2ALMNA | |
| SCHEMBL97125 | 0.81 | HPGD (0.69) | HPGDALDH1A1HSD17B10POLBL3MBTL3 | |
| SCHEMBL24185725 | 0.81 | HPGD (0.96) | HPGDALDH1A1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL21590292 | 0.81 | HPGD (0.89) | HPGDALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| WO-2022011338-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022011337-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2022-01-13 | — | — | WO | disclosed |
| EP-3209296-B1 | ETHYL N-BOC PIPERIDINYL PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3209296-B1 | ETHYL N-BOC PIPERIDINYL PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10072025-B2 | Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-09-11 | — | — | US | disclosed |
| EP-3209296-A1 | ETHYL N-BOC PIPERIDINYL PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170240567-A1 | ETHYL N-BOC PIPERIDINYL PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240567-A1 | ETHYL N-BOC PIPERIDINYL PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240567-A1 | ETHYL N-BOC PIPERIDINYL PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, MAPKAPK2, MAP3K20 | HPGD 4226/4885ALDH1A1 4878/4885HSD17B10 4342/4885 |
| US-20170240567-A1 | ETHYL N-BOC PIPERIDINYL PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | HPGD 853/4885ALDH1A1 2779/4885HSD17B10 4121/4885 |
| US-10072025-B2 | Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors | JAK1, JAK2, JAK3 | HPGD 853/4885ALDH1A1 2779/4885HSD17B10 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.